CYP3A4 and steatosis: Tocilizumab at 232 μg/mL had no effect on CYP3A4-mediated terfenadine metabolism (Figure 1D), but it increased steatosis (Figure 1E) and production of reactive oxygen species (ROS) after 10 days of treatment (Figure 1F).